向 #ESMO26 下消化道专题讨论小组提出一个尖锐的问题：
在 BREAKWATER 研究之后，如果 BRAF V600E mCRC 在 FOLFOX + encorafenib/cetuximab 治疗下进展，我们能否改用 FOLFIRI + EC，或反之？
更换化疗骨架能否在疾病进展后仍保留靶向治疗的获益？
37 浏览 · 1 赞 · 0 转发 · 0 回复
STARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma
https://esmocongress.esmo.orgEncorafenib plus cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E metastatic colorectal cancer (mCRC) patients (pts) progressing on EC: Results from the ECLYPse phase II trial
https://esmocongress.esmo.org- **标题 / Title：** Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
https://esmocongress.esmo.org- **标题 / Title：** Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
https://esmocongress.esmo.org来源：Targeted Oncology · x.com